An increasing prevalence of cancer, brain tumors, and other neurological diseases, rising adoption of these instruments in surgery centers, growing preference for Minimally Invasive Surgeries, and technological advancements in the device are amongst few factors expected to drive the market.
Gamma knife therapy is used for treatment of various brain and neurological disorders such as brain tumors, brain metastases, epilepsy, and arteriovenous malformations.
Demand for these instruments in surgery centers is growing due to their various advantages such as safety, micro precision, lack of postsurgical complications, and lack of incisions.
Technological advancements have improved precision in surgery.
For instance, upgradation of Leksell Gamma Knife models U, B, C/4C, and Perfexion to Icon provided micro precision in surgery and boosted adoption of this device in surgery centers.
According to reports published by Elekta AB, approximately 70,000 patients undergo gamma knife surgery each year. This number is expected to increase over the forecast period owing to rising prevalence of target diseases and increasing preference for MIS.
In addition, growing demand for MIS over open surgeries is one of the key factors responsible for increasing adoption of this therapy.
Gamma knife treatment procedure results in fewer traumas and faster recovery as compared to open surgeries.
It helps reduce hospital stays, thus ensuring economic viability and reduction in medical expenses. Lack of incisions and postsurgical complications are key factors responsible for boosting demand for minimally invasive surgeries.
The Asia Pacific region is anticipated to witness lucrative growth over the next decade owing to rising incidence of cancer, developments in healthcare infrastructure, and rapid economic development across major emerging economies. It is expected to grow at a CAGR of around 4% over the forecast period.
Elekta AB is the only player operating in this market since Gamma Knife is a patent-protected trademark product of the company.
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study
RyboDyn joins Lilly Gateway Labs' innovation hub
GRAIL reports positive results from Galleri multi-cancer early detection test registrational study